
Every so often, the market serves up a handful of charts that practically nudge you to take a closer look. You know the type, steady higher lows, clean breakouts, and that subtle shift in momentum that hints at a story unfolding beneath the surface. In this piece, we’re turning the spotlight on three ASX-listed stocks whose price action has been speaking in a clear and confident tone. These aren’t wild speculative swings or one-off spikes; they’re structured uptrends that have earned their place on watchlists through consistent behaviour.

We believe CSL Limited (ASX: CSL) remains one of the highest-quality global healthcare franchises listed on the ASX, with FY25 marking a clear re-acceleration in earnings quality, cash flow conversion, and strategic clarity. While the share price has periodically struggled to reflect this underlying strength, we view CSL as misunderstood rather than mis-executing.

LaserBond (ASX: LBL) has entered a structurally stronger period after FY25 delivered clear evidence of operating leverage, improved manufacturing efficiencies, and accelerating adoption of its surface-engineered technologies across mining, energy, defence, and agricultural markets. With its patented LaserBond® cladding and composite coating systems now demonstrating superior lifecycle economics versus traditional wear-resistance methods, the company is positioned as a high-margin engineering solutions provider rather than a cyclical industrial.

Sunrise Energy Metals (ASX: SRL) is advancing one of the Western world’s most strategically significant battery-materials developments: the Sunrise Nickel-Cobalt-Scandium Project in NSW, a globally large, long-life, ESG-aligned source of critical minerals essential for EVs, aerospace alloys, defence technologies and high-performance fuel cells. Backed by strong balance sheet discipline, rising government engagement, escalating Western supply-security policies, and material advancement across strategic partnerships during 2025, Sunrise enters 2026 with a profile we view as deeply undervalued relative to its strategic optionality.

Recce has recently attracted attention because it’s advancing drug candidates against serious infections, a space with significant potential if late-stage trials succeed. That kind of promise is why some market watchers see upside in RCE’s shares. On the flip side, the company remains unprofitable, with no consistent earnings or predictable cash flow, so it’s still a speculative biotech rather than a stable performer.

Cettire (ASX: CTT) share price recently had a breakout. But it is in a bit of limbo; enough promise remains that a rebound could be on the cards, but enough uncertainty that it’s far from a safe bet. On one hand, the company is forecast to post healthy earnings-per-share growth over the next few years and has a pretty low price-to-sales ratio compared with peers, suggesting some latent value. On the other hand, consensus analyst targets hover modestly, some even see a drop, and many believe any upside beyond roughly one Australian dollar a share depends on improvements that aren’t guaranteed.